微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 2.92% | 148.18% | 521.28% | 62/157 | 1.37% | 泽璟制药 | 44.02% | 行业排名> |
| 2026-03-31 | 0.47% | 119.18% | 101.85% | 107/157 | 0.06% | 泽璟制药 | 45.29% | 行业排名> |
| 2025-12-31 | -25.45% | -20.56% | -454.47% | 134/157 | -4.46% | 兴齐眼药 | 38.62% | 行业排名> |
| 2025-09-30 | -4.59% | 11.22% | 24.26% | 126/157 | 1.31% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | -6.06% | -1.34% | -147.35% | 133/157 | 0.3% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | -2.45% | -40.8% | 88.39% | 131/157 | -0.34% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | -21.11% | -21.95% | -308.32% | 133/157 | -9.62% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | -5.17% | 41.98% | 13.55% | 129/157 | 4.28% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | -5.98% | 10.34% | -243.68% | 132/157 | 2.69% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | -1.74% | 15.12% | 89.95% | 125/157 | 2.35% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | -17.31% | -11.61% | -94.28% | 130/157 | -1% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | -8.91% | -74.36% | -33.58% | 129/157 | 2.36% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | -6.67% | -436.87% | -225.37% | 129/157 | 1.48% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | -2.05% | -246.43% | 86.78% | 126/157 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | -15.51% | -864.04% | -203.52% | 129/157 | 0.79% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | -5.11% | -194.63% | -358.08% | 121/157 | 2.86% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 1.98% | -23.55% | 41.43% | 86/157 | 2.21% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 1.4% | -40.17% | -31.03% | 74/157 | 1.59% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 2.03% | -59.32% | -62.41% | 98/157 | 0.84% | ST人福 | 6.82% | 行业排名> |
| 2021-09-30 | 5.4% | -52.34% | 108.49% | 75/157 | 4.46% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 2.59% | -4.78% | 10.68% | 86/157 | 2.99% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 2.34% | -52.24% | -53.11% | 59/157 | 2.49% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 4.99% | -51.27% | -55.96% | 83/157 | 3.8% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 11.33% | 0.35% | 316.54% | 30/157 | 3.13% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 2.72% | -38.6% | -44.49% | 77/157 | 4.28% | 中哲精化 | 45.32% | 行业排名> |
| 2020-03-31 | 4.9% | 89.19% | -52.15% | 13/157 | 2.23% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 10.24% | 23.67% | -9.3% | 55/157 | 2.57% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 11.29% | -9.17% | 154.85% | 24/157 | 7.58% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 4.43% | -3.9% | 71.04% | 55/157 | 5.02% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 2.59% | 4.44% | -68.72% | 41/157 | 2.45% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 8.28% | -10.2% | -33.39% | 61/157 | 7.16% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 12.43% | 54.6% | 169.63% | 13/157 | 7.21% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 4.61% | 8.98% | 85.89% | 45/157 | 4.63% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 2.48% | 3.77% | -73.1% | 43/157 | 2.57% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 9.22% | 10.95% | 14.68% | 54/157 | 9.62% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 8.04% | -10.86% | 90.07% | 42/157 | 8.31% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 4.23% | 14.95% | 76.99% | 57/157 | 5.56% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 2.39% | 3.02% | -71.24% | 37/157 | 2.1% | 中哲精化 | 54.24% | 行业排名> |
| 2016-12-31 | 8.31% | -51.2% | -7.87% | 64/157 | 6.05% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 9.02% | -41.08% | 145.11% | 29/157 | 5.64% | ST南新 | 81.7% | 行业排名> |
| 2016-06-30 | 3.68% | -74.34% | 58.62% | 50/157 | 3.52% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 2.32% | 2% | -86.38% | 34/157 | 2.69% | 贝达药业 | 16.78% | 行业排名> |